SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics announced the appointment of Jennifer McDonough…

Palvella Therapeutics Inc. · PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

Palvella Therapeutics announced the appointment of Jennifer McDonough as Senior Vice President of Market Access and Patient Services, leveraging her experience from Krystal Biotech's successful VYJUVEK® launch to prepare for a potential U.S. commercialization of QTORIN™ rapamycin for microcystic lymphatic malformations. The move signals advancing commercial readiness ahead of a potential FDA approval, though no new clinical or regulatory milestones were announced.

  • Jennifer McDonough appointed as SVP of Market Access and Patient Services at Palvella Therapeutics.
  • McDonough previously led patient access and operations at Krystal Biotech, contributing to VYJUVEK®'s growth to $389M in annual sales by 2025 after its 2023 FDA approval.
  • Palvella is preparing for a potential near-term U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, following positive Phase 3 SELVA results.
  • No new clinical data, regulatory decisions, or financial figures were disclosed in the press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access